

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REQUEST FOR ACCESS TO AN ABANDONED APPLICATION UNDER 37 CFR 1.14

Bring completed form to:

File Information Unit, Room 2E04

2900 Crystal Drive

Arlington, VA 22202-3514

Telephone: (703) 308-2733

JAN 28 2008

File Information Unit

In re Application of

Application Number

09/256,388

Filed

2/24/99

Paper No. #12.

I hereby request access under 37 CFR 1.14(a)(1)(iv) to the application file record of the above-identified ABANDONED application, which is not within the file jacket of a pending Continued Prosecution Application (CPA) (37 CFR 1.53(d)) and which is identified in, or to which a benefit is claimed, in the following document (as shown in the attachment):

United States Patent Application Publication No. _____, page, _____ line _____

United States Patent Number _____, column _____, line, _____ or

WIPO Pub. No. _____, page _____, line _____

Related Information About Access to Applications Maintained in the Image File Wrapper System (IFW) and Access to Pending Applications in General

A member of the public, acting without a power to inspect, cannot order applications maintained in the IFW system through the FIU. If the member of the public is entitled to a copy of the application file, then the file is made available through the Public Patent Application Information Retrieval system (Public PAIR) on the USPTO internet web site (www.uspto.gov). Terminals that allow access to Public PAIR are available in the Public Search Room. The member of the public may also be entitled to obtain a copy of all or part of the application file upon payment of the appropriate fee. Such copies must be purchased through the Office of Public Records upon payment of the appropriate fee (37 CFR 1.19(b)).

For published applications that are still pending, a member of the public may obtain a copy of:

the file contents; the pending application as originally filed; or any document in the file of the pending application.

For unpublished applications that are still pending:

- (1) If the benefit of the pending application is claimed under 35 U.S.C. 119(e), 120, 121, or 365 in another application that has: (a) issued as a U.S. patent, or (b) published as a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of: the file contents; the pending application as originally filed; or any document in the file of the pending application.
- (2) If the application is incorporated by reference or otherwise identified in a U.S. patent, a statutory invention registration, a U.S. patent application publication, or an international patent application publication in accordance with PCT Article 21(2), a member of the public may obtain a copy of the pending application as originally filed.

Aziel Tesfay
Signature
Aziel Tesfay
Typed or printed name

1/28/08
Date

Registration Number, if applicable

703-486-1150

Telephone Number

FOR PTO USE ONLY

Approved by *Du*
(initials)Unit: *JAN 28 2008*

File Information Unit

This collection of information is required by 37 CFR 1.11 and 1.14. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. BRING TO: File Information Unit, Room 2E04, 2900 Crystal Drive, Arlington, Virginia.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



US006015557A

United States Patent [19]

Tobinick et al.

[11] **Patent Number:** 6,015,557[45] **Date of Patent:** Jan. 18, 2000

#12

[54] **TUMOR NECROSIS FACTOR ANTAGONISTS
FOR THE TREATMENT OF
NEUROLOGICAL DISORDERS**

5,656,272 8/1997 Le et al. .

5,795,967 8/1998 Aggarwal et al. .

[76] **Inventors:** Edward L. Tobinick; Arthur Jerome
Tobinick, both of 100 UCLA Medical
Plz., Suite 205, Los Angeles, Calif.
90024-6903

Primary Examiner—William R. A. Jarvis
Attorney, Agent, or Firm—Ezra Sutton

[57] **ABSTRACT**[21] **Appl. No.:** 09/275,070[22] **Filed:** Mar. 23, 1999**Related U.S. Application Data**

[63] Continuation-in-part of application No. 09/256,388, Feb. 24,
1999, abandoned.

[51] **Int. Cl.⁷** A61K 39/395; A61K 31/495;
A61K 31/50; A61K 31/42

[52] **U.S. Cl.** 424/134.1; 514/249; 514/378

[58] **Field of Search** 424/134.1; 514/249,
514/378

A method for inhibiting the action of TNF for treating neurological conditions in a human by administering a TNF antagonist for reducing damage to neuronal tissue or for modulating the immune response affecting neuronal tissue of the human. The TNF antagonist administered is selected from the group consisting of etanercept and infliximab. The TNF antagonist is administered subcutaneously, intravenously, intrathecally, or intramuscularly.

Methotrexate or Leflunomide may be administered concurrently with the TNF antagonist for demyelinating diseases and certain other neurological disorders.

[56] **References Cited****U.S. PATENT DOCUMENTS**

5,605,690 2/1997 Jacobs et al. .

47 Claims, No Drawings